Compo-Q: New small molecules for the treatment of prion and neurodegenerative diseases(e.g. Alzheimer’s disease)

Scientists at the University of Duesseldorf and the University of Erlangen have developed new small molecules which can be used for the treatment of diseases characterized by the presence of misfolded

proteins. Examples for such medical conditions are prion diseases, e.g. CJD, as well as neurodegenerative (e.g. Alzheimer’s disease) or neuropsychiatric diseases. Compo-Q have a structural relationship to quinacrine which is considered to be one of the most promising candidate for the clinical therapy of prion diseases. In Compo-Q the “modified quinacrine” is covalently linked to a derivative of another substance which has been proven effective against prion diseases in vitro.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

Alle Nachrichten aus der Kategorie: Technology Offerings

Zurück zur Startseite

Kommentare (0)

Schreib Kommentar

Neueste Beiträge

Researchers break magnetic memory speed record

Advance could lead to new generation of ultrafast computer chips that retain data even when there is no power. Spintronic devices are attractive alternatives to conventional computer chips, providing digital…

Tracing the source of illicit sand–can it be done?

Research presented at the 2020 GSA Annual Meeting. If you’ve visited the beach recently, you might think sand is ubiquitous. But in construction uses, the perfect sand and gravel is…

Location and extent of coral reefs mapped worldwide using advanced AI

Nearly 75% of the world’s coral reefs are under threat from global stressors such as climate change and local stressors such as overfishing and coastal development. Those working to understand…

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close